Clinical trials: Acne Inversa
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Hidradenitis Suppurativa
To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
The trial is a 12-week phase 2 study. Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12 in subjects with moderate to severe hidradenitis suppurativa.
- Trial name
- HIDRI2007 (NCT00827996)
- Testing
- adalimumab
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Florida Academic Dermatology Centers
Hidradenitis Suppurativa
MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder. Although adalimumab is recently licensed for moderate to severe HS, many cases fail to respond or relapse during treatment.
- Trial name
- NCT02643654
- Testing
- MABp1
- Where
- Greece
- Volunteers
- 20 people
- Sponsor
- Evangelos J. Giamarellos-Bourboulis, M.D.
Hidradenitis Suppurativa (HS)
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.
- Trial name
- NCT07783542
- Testing
- ORKA-002
- Where
- 25 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Oruka Therapeutics, Inc.
Hidradenitis Suppurativa
Etanercept in Hidradenitis Suppurativa
The rationale of the protocol is based on the reported beneficiary results of case-patients by the administration of other anti-TNF drug (infliximab) in separate cases on the grounds of a probable autoimmune predisposition of the…
- Trial name
- NCT00329823
- Testing
- Etanercept sc 50mg per week for 12 weeks
- Where
- Greece
- Volunteers
- 10 people
- Sponsor
- University of Athens
Hidradenitis Suppurativa
Spironolactone for Hidradenitis Suppurativa
The purpose of this study is to evaluate if the drug spironolactone - which is used to treat acne and male pattern hair growth in women - is effective in treating hidradenitis suppurativa in females and which dose of the drug…
- Trial name
- NCT04100083
- Testing
- Spironolactone 50 MG, Spironolactone 100mg, Spironolactone 200 mg
- Sponsor
- Medical University of South Carolina
Hidradenitis Suppurativa, Acne Inversa
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period.
- Trial name
- NCT04476043
- Testing
- INCB054707
- Where
- 40 sites in United States, Canada and 4 more
- Volunteers
- 209 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week…
- Trial name
- STOP-HS1 (NCT05620823)
- Testing
- Povorcitinib
- Where
- 104 sites in United States, Austria and 10 more
- Volunteers
- 608 people
- Sponsor
- Incyte Corporation